245 related articles for article (PubMed ID: 29854848)
1. Recombinant Enolase of
Arce-Fonseca M; González-Vázquez MC; Rodríguez-Morales O; Graullera-Rivera V; Aranda-Fraustro A; Reyes PA; Carabarin-Lima A; Rosales-Encina JL
J Immunol Res; 2018; 2018():8964085. PubMed ID: 29854848
[No Abstract] [Full Text] [Related]
2. Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice.
Martinez-Campos V; Martinez-Vega P; Ramirez-Sierra MJ; Rosado-Vallado M; Seid CA; Hudspeth EM; Wei J; Liu Z; Kwityn C; Hammond M; Ortega-López J; Zhan B; Hotez PJ; Bottazzi ME; Dumonteil E
Vaccine; 2015 Aug; 33(36):4505-12. PubMed ID: 26192358
[TBL] [Abstract][Full Text] [Related]
3. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice.
Bhatia V; Garg NJ
Clin Vaccine Immunol; 2008 Aug; 15(8):1158-64. PubMed ID: 18550728
[TBL] [Abstract][Full Text] [Related]
4.
Gupta S; Salgado-Jiménez B; Lokugamage N; Vázquez-Chagoyán JC; Garg NJ
Front Immunol; 2019; 10():1456. PubMed ID: 31293599
[No Abstract] [Full Text] [Related]
5. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
Bivona AE; Sánchez Alberti A; Matos MN; Cerny N; Cardoso AC; Morales C; González G; Cazorla SI; Malchiodi EL
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006384. PubMed ID: 29601585
[TBL] [Abstract][Full Text] [Related]
6. A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.
Barry MA; Wang Q; Jones KM; Heffernan MJ; Buhaya MH; Beaumier CM; Keegan BP; Zhan B; Dumonteil E; Bottazzi ME; Hotez PJ
Hum Vaccin Immunother; 2016 Apr; 12(4):976-87. PubMed ID: 26890466
[TBL] [Abstract][Full Text] [Related]
7. Recombinant Mycobacterium bovis BCG is a promising platform to develop vaccines against Trypansoma cruzi infection.
Bontempi I; Leal K; Prochetto E; Díaz G; Cabrera G; Bortolotti A; Morbidoni HR; Borsuk S; Dellagostin O; Marcipar I
Clin Exp Immunol; 2020 Sep; 201(3):306-316. PubMed ID: 32464684
[TBL] [Abstract][Full Text] [Related]
8. Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against
Cerny N; Bivona AE; Sanchez Alberti A; Trinitario SN; Morales C; Cardoso Landaburu A; Cazorla SI; Malchiodi EL
Front Immunol; 2020; 11():565142. PubMed ID: 33162979
[TBL] [Abstract][Full Text] [Related]
9. TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice.
Hegazy-Hassan W; Zepeda-Escobar JA; Ochoa-García L; Contreras-Ortíz JME; Tenorio-Borroto E; Barbabosa-Pliego A; Aparicio-Burgos JE; Oros-Pantoja R; Rivas-Santiago B; Díaz-Albiter H; Garg NJ; Vázquez-Chagoyán JC
Vaccine; 2019 Jan; 37(2):248-257. PubMed ID: 30497833
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.
Gupta S; Garg NJ
PLoS Negl Trop Dis; 2010 Aug; 4(8):e797. PubMed ID: 20706586
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease.
Bontempi IA; Vicco MH; Cabrera G; Villar SR; González FB; Roggero EA; Ameloot P; Callewaert N; Pérez AR; Marcipar IS
Vaccine; 2015 Mar; 33(10):1274-83. PubMed ID: 25625671
[TBL] [Abstract][Full Text] [Related]
12. Preventive and therapeutic DNA vaccination partially protect dogs against an infectious challenge with Trypanosoma cruzi.
Quijano-Hernández IA; Castro-Barcena A; Vázquez-Chagoyán JC; Bolio-González ME; Ortega-López J; Dumonteil E
Vaccine; 2013 Apr; 31(18):2246-52. PubMed ID: 23499599
[TBL] [Abstract][Full Text] [Related]
13. Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection.
Schnapp AR; Eickhoff CS; Scharfstein J; Hoft DF
Microbes Infect; 2002 Jul; 4(8):805-13. PubMed ID: 12270727
[TBL] [Abstract][Full Text] [Related]
14. From genome screening to creation of vaccine against Trypanosoma cruzi by use of immunoinformatics.
Teh-Poot C; Tzec-Arjona E; Martínez-Vega P; Ramirez-Sierra MJ; Rosado-Vallado M; Dumonteil E
J Infect Dis; 2015 Jan; 211(2):258-66. PubMed ID: 25070943
[TBL] [Abstract][Full Text] [Related]
15. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
Schnapp AR; Eickhoff CS; Sizemore D; Curtiss R; Hoft DF
Infect Immun; 2002 Sep; 70(9):5065-74. PubMed ID: 12183554
[TBL] [Abstract][Full Text] [Related]
16. Experimental Chagas disease in Balb/c mice previously vaccinated with T. rangeli. II. The innate immune response shows immunological memory: reality or fiction?
Basso B; Marini V
Immunobiology; 2015 Mar; 220(3):428-36. PubMed ID: 25454810
[TBL] [Abstract][Full Text] [Related]
17. A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection.
Barry MA; Versteeg L; Wang Q; Pollet J; Zhan B; Gusovsky F; Bottazzi ME; Hotez PJ; Jones KM
PLoS Negl Trop Dis; 2019 May; 13(5):e0007413. PubMed ID: 31145733
[TBL] [Abstract][Full Text] [Related]
18. Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease.
Seid CA; Jones KM; Pollet J; Keegan B; Hudspeth E; Hammond M; Wei J; McAtee CP; Versteeg L; Gutierrez A; Liu Z; Zhan B; Respress JL; Strych U; Bottazzi ME; Hotez PJ
Hum Vaccin Immunother; 2017 Mar; 13(3):621-633. PubMed ID: 27737611
[TBL] [Abstract][Full Text] [Related]
19. Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes.
Frank FM; Petray PB; Cazorla SI; Muñoz MC; Corral RS; Malchiodi EL
Vaccine; 2003 Dec; 22(1):77-86. PubMed ID: 14604574
[TBL] [Abstract][Full Text] [Related]
20. [TH1 response in the experimental infection with Trypanosoma cruzi].
Cardoni RL; Antúnez MI; Abrami AA
Medicina (B Aires); 1999; 59 Suppl 2():84-90. PubMed ID: 10668248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
